Recardio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.recardio.eu
Clinical Trials
9
Active:6
Completed:2
Trial Phases
3 Phases
Phase 1:6
Phase 2:2
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (66.7%)Phase 2
2 (22.2%)Phase 3
1 (11.1%)Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
Phase 3
Not yet recruiting
- Conditions
- ST Elevation Myocardial Infarction
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Recardio, Inc.
- Target Recruit Count
- 4100
- Registration Number
- NCT05881382
Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction
Phase 2
Completed
- Conditions
- Acute Myocardial InfarctionAcute Myocardial IschemiaSTEMI - ST Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- Recardio, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03486080
- Locations
- 🇦🇹
Clinical department of Cardiology, Graz, Austria
🇦🇹Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria
🇧🇪Algemeen Stedelijk Ziekenhuis Aalst, Aalst, Belgium
News
Kancera Advances Cardiovascular Drug Pipeline with Recardio Partnership and FDA Engagement
Kancera AB has partnered with US biotech Recardio Inc. to create a cardiovascular disease-focused specialty care company, with Recardio licensing candidate drugs KAND567 and KAND145.